HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

58.800

-2.200-3.61%

Volume:272.20K

Turnover:15.44M

Market Cap:10.03B

PE:-31.70

High:59.800

Open:59.000

Low:54.000

Close:61.000

52wk High:95.800

52wk Low:54.000

Shares:170.55M

HK Float Shares:170.55M

Volume Ratio:1.14

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.855

ROE:--

ROA:--

PB:-151.39

PE(LYR):-31.70

PS:49.11

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial

MT Newswires Live

Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China

Bulletin Express

RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06938"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":58.8,"timestamp":1772611695096,"preClose":61,"halted":0,"volume":272200,"delay":0,"changeRate":-0.03606557377049185,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"Closed","change":-2.2,"latestTime":"03-04 16:08:15","open":59,"high":59.8,"low":54,"amount":15435300,"amplitude":0.095082,"askPrice":58.8,"askSize":5400,"bidPrice":57.5,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61,"openAndCloseTimeList":[[1772587800000,1772596800000],[1772600400000,1772611200000]],"volumeRatio":1.141491,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-1.855,"volumeRatio":1.141491,"shares":170554910,"dividePrice":0,"high":59.8,"amplitude":0.095082,"preClose":61,"low":54,"week52Low":54,"pbRate":"-151.39","psRate":"49.11","week52High":95.8,"institutionHeld":0,"latestPrice":58.8,"committee":-0.636364,"eps":-1.855,"divideRate":0,"volume":272200,"delay":0,"ttmEps":-1.502,"open":59,"prevYearClose":57.97,"prevWeekClose":68.5,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":71.5,"twentyDayClose":68.8,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-03","current":-37.882823,"percent":1,"low":-50.513246,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"high":-41.67233,"avg":-47.34064,"sd":2.663177,"marketCap":10403849510},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-03","current":-41.67233,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"marketCap":10403849510}],"updateTime":1772601887232},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616016068","title":"Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616016068","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616016068?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:56","pubTimestamp":1772423773,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  said a phase 3 clinical of RBD7022 is about to begin after the drug's collaborator, Qilu Pharmaceutical, completed public registration, according to a Hong Kong bourse filing Monday.The drug will be studied as a treatment for high cholesterol to reduce the risk of heart disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1108221887","title":"Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1108221887","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108221887?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:22","pubTimestamp":1772414532,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1132294830","title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132294830?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:18","pubTimestamp":1772410695,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4134","BK1161","III"],"gpt_icon":0},{"id":"2616258877","title":"Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2616258877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616258877?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:09","pubTimestamp":1772410146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZO04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/06938\",params:#limit:6,delay:false,,,undefined,":[]}}